Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: Results of a randomized crossover trial

Haematologica

Volumn 102, Issue 3, 2017, Pages 600-609

  Pantin, Jeremy ^a   Purev, Enkhtsetseg ^b   Tian, Xin ^b   Cook, Lisa ^b   Donohue Jerussi, Theresa ^b   Cho, Elena ^b   Reger, Robert ^b   Hsieh, Matthew ^b   Khuu, Hanh ^c   Calandra, Gary ^d   Geller, Nancy L ^b   Childs, Richard W ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Sanofi Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; PLERIXAFOR; HETEROCYCLIC COMPOUND;

ADULT; ALLOTRANSPLANTATION; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; LYMPHOCYTE COUNT; MALE; MONOCYTE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; TREATMENT OUTCOME; ADVERSE EFFECTS; CFU COUNTING; CLINICAL TRIAL; CYTOLOGY; DONOR; DRUG EFFECTS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; PROCEDURES; TIME FACTOR; YOUNG ADULT;

ADULT; ANTIGENS, CD34; COLONY-FORMING UNITS ASSAY; CROSS-OVER STUDIES; FEMALE; HEALTHY VOLUNTEERS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TISSUE DONORS; YOUNG ADULT;

EID: 85014428652     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.147132     Document Type: Article

References (31)

1. Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant. 2000;26(1):1-16.
2. Petit I, Szyper-Kravitz M, Nagler A, et al. GCSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3(7): 687-694.
3. Brissot E, Chevallier P, Guillaume T, et al. Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors. Bone Marrow Transplant. 2009;44(9):613-615.
4. Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol. 1999;105 (3):775-779.
5. Pastore D, Specchia G, Mestice A, et al. Good and poor CD34+ cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells. Bone Marrow Transplant. 2004;33(11):1083-1087.
6. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol. 1997;98(3):736-744.
7. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):2035-2042.
8. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185(1): 111-120.
9. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004;22(6):1095-1102.
10. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8): 2728-2730.
11. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201(8):1307-1318.
12. Brave M, Farrell A, Ching Lin S, et al. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology. 2010;78(3-4):282-288.
13. Donahue RE, Jin P, Bonifacino AC, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood. 2009;114(12):2530-2541.
14. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;11 2 (4):990-998.
15. Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood. 2006;107(9): 3772-3778.
16. Lemery SJ, Hsieh MM, Smith A, et al. A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol. 2011;153(1):66-75.
17. Lack NA, Green B, Dale DC, et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther. 2005;77(5):427-436.
18. Stewart DA, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009;15(1):39-46.
19. Hubel K, Liles WC, Broxmeyer HE, et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther. 2004;1(3):165-172.
20. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5(3):213-226.
21. Armitage S, Hargreaves R, Samson D, Brennan M, Kanfer E, Navarrete C. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant. 1997;20(7):587-591.
22. Lundqvist A, Smith AL, Takahashi Y, et al. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol. 2013;191(12): 6241-6249.
23. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530-4540.
24. Rosenbaum ER, O'Connell B, Cottler-Fox M. Validation of a formula for predicting daily CD34(+) cell collection by leukapheresis. Cytotherapy. 2012;14(4):461-466.
25. Singhal S, Powles R, Treleaven J, et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant. 2000;26(5):489-496.
26. Winters JL. Complications of donor apheresis. J Clin Apher. 2006;21(2):132-141.
27. Bolan CD, Carter CS, Wesley RA, et al. Prospective evaluation of cell kinetics, yields and donor experiences during a single largevolume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells. Br J Haematol. 2003;120(5):801-807.
28. Sloand EM, Kim S, Maciejewski JP, et al. Pharmacologic doses of granulocyte colonystimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000;95(7):2269-2274.
29. Franzke A, Piao W, Lauber J, et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood. 2003;102(2):734-739.
30. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
31. Arbez J, Saas P, Lamarthee B, et al. Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graftversus-host-disease. Cytotherapy. 2015;17 (7):948-955.